0001209191-18-025031.txt : 20180416 0001209191-18-025031.hdr.sgml : 20180416 20180416173113 ACCESSION NUMBER: 0001209191-18-025031 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180412 FILED AS OF DATE: 20180416 DATE AS OF CHANGE: 20180416 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Barth Jay CENTRAL INDEX KEY: 0001601896 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 18757447 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS INC CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-04-12 0 0001178879 AMICUS THERAPEUTICS INC FOLD 0001601896 Barth Jay C/O AMICUS THERAPEUTICS, INC. 1 CEDAR BROOK DRIVE CRANBURY NJ 08512 0 1 0 0 Chief Medical Officer Common Stock 2018-04-12 4 M 0 5000 2.29 A 90409 D Common Stock 2018-04-12 4 S 0 5000 14.7204 D 85409 D Common Stock 125 I By Daughter Stock Options (right to buy) 2.29 2018-04-12 4 M 0 5000 0.00 D 2024-03-03 Common Stock 5000 100000 D The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2017. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.61 to $14.86. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. All of the options were fully vested and exercisable as of April 12, 2018. /s/ Jay Barth 2018-04-16